Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.61 |
| ▸ | MMP13 | P45452 | 16/20 | 0.61 |
| ▸ | MMP2 | P08253 | 3/20 | 0.52 |
| ▸ | MMP9 | P14780 | 3/20 | 0.52 |
| ▸ | MMP8 | P22894 | 3/20 | 0.52 |
| ▸ | MMP3 | P08254 | 2/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17462006 | 0.86 | CYP3A4 (0.52) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL16004952 | 0.85 | MMP1 (0.52) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL16013385 | 0.83 | MMP1 (0.62) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL6796931 | 0.81 | MMP1 (0.58) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL7208581 | 0.80 | MMP1 (0.77) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL6801915 | 0.80 | MMP1 (0.59) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL27618200 | 0.79 | MMP1 (0.46) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL27415619 | 0.78 | MMP1 (0.76) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL643982 | 0.78 | MMP1 (0.55) | MMP1MMP13MMP2MMP9MMP8 | |
| SCHEMBL6962211 | 0.77 | MMP1 (0.83) | MMP1MMP13MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9409864-B2 | Sulfonamide TRPA1 receptor antagonists | ARIO PHARMA LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | ARIO PHARMA LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| EP-2964615-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | Ario Pharma Limited (GB) | 2016-01-13 | — | — | EP | disclosed |
| EP-2900642-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2014135617-A1 | NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS | PHARMESTE S.R.L. IN LIQUIDATION (IT) | 2014-09-12 | — | — | WO | disclosed |
| EP-2774919-A1 | Novel sulfonamide TRPA1 receptor antagonists | PHARMESTE S.R.L. IN LIQUIDAZIONE (IT) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | TRPA1, TRPV1, TRPV5 | MMP1 2584/4885MMP13 3501/4885MMP2 3774/4885 |
| US-20160024009-A1 | Novel Sulfonamide TRPA1 Receptor Antagonists | TRPA1, TRPV1, TRPV2 | MMP1 3849/4885MMP13 4270/4885MMP2 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.